For Immediate Release:

Canadian Physicians for Life comment on RU-486 (mifepristone)

November 28, 2013

The potent anti-hormone RU-486 has caused the deaths of millions of unborn children worldwide. We are saddened that any number of the smallest preborn Canadian children could soon be added to that list of deaths. RU-486 can and has been used to surreptitiously poison a wanted pregnancy. RU-486 abortions also require a companion drug, misoprostol, whose manufacturer has stated:

“Serious adverse events reported following off-label use of misoprostol in pregnant women include maternal or fetal death; uterine hyperstimulation, rupture or perforation requiring uterine surgical repair, hysterectomy or salpingo-oophorectomy; amniotic fluid embolism; severe vaginal bleeding, retained placenta, shock, fetal bradycardia and pelvic pain.”

This is death we are talking about, not just of the unborn babies but sometimes of the mothers themselves. Maternal death in the course of the unnecessary and intentional destruction of a child should be seen as a special tragedy and a repudiation of all that is good in the Canadian medical system. We protest the importation into Canada of RU-486, a grievous misuse of medical science.
– 30 –


Recent Posts

You Might Also Like

  • By: CPL Office on January 17, 2020

    Vancouver area hospice is asking the government to reconsider their proposal to give up $750,000 a year in funding so that it not be required to violate its mandate of care and compassion for patients by providing Medical Assistance in Dying (MAiD) at its facility. The health authority’s demand is unnecessary, the hospice contends,

  • By: CPL Office on July 30, 2015

    OTTAWA – Health Canada confirmed yesterday that RU-486 has been approved for use in Canada. It is a two drug combination that causes an abortion and is used during the first trimester of pregnancy. “No drug is without risk, but the risks associated with RU-486 are well known,” says Dr. Laura Lewis, an Ontario

Follow US:

Want to become a member?


Vital Bylines: Get news and opportunities weekly from CPL.